Manremyc, a CataloniaBio & HealthTech member, has closed a €250,000 round of investment on the Capital Cell crowdfunding platform, with 45 new small investors joining the company’s stakeholders.

Instead of developing a drug to cure tuberculosis or a vaccine to prevent it, Manremyc has developed a probiotic that is highly effective at preventing the spread of this disease. Development of this product is cheaper, faster and less risky. Now the company has raised this capital, it will strengthen the launch to market of Nyaditum resae® after having signed 65 sales deals with pharmaceutical companies.

“In late September, we’ll have the first commercial lot manufactured for Kenya and Vietnam. We’re also developing a new galenic formula, in stick format instead of capsules, designed for the market in the Philippines,” explains Dr Pere-Joan Cardona, co-inventor of the probiotic and founder of the company in 2013.

Manremyc hopes to gain authorisation from the European Food Safety Authority later this year, which will help open up the market in many other countries.

Photo: Isabel Amat, Pere-Joan Cardona and Jaume Amat, co-founders of the biotechnology firm - © Manremyc